Abstract:Background: Much effort has been expended in exploring the connections between transcriptome, disease and drug, based on the premise that drug induced perturbations in the transcriptome will affect the phenotype and finally help to cure a disease. MicroRNAs (miRNAs) play a key role in the regulation of the transcriptome and have been identified as a key mediator in human disease and drug response. However, even if miRNA expression can be precisely detected, the information regarding miRNAs action on a particular part of the transcriptome is still lacking. Here, we introduced a novel concept, the Context-specific MiRNA activity (CoMi activity), to reflect a miRNA's regulation effect on a context specific gene set, by calculating the statistical difference between the distributions of its target gene expression and non-target gene expression. In this study we investigate whether CoMi activity could provide a novel perspective on miRNA mechanisms of action in disease and drug response, and facilitate in silico drug screening. Results: Using breast cancer as an example, we examined the CoMi activity based on a Gene Ontology (GO) term as context. Then we constructed a differential CoMi activity network (cancer vs. normal), based on the comi activity represents as a link between miRNAs and GO terms. (e.g. hsa-miR-27a's regulation on GO term "apoptosis"). The topological analysis of the generated network demonstrated that the cancer specific CoMi network is a scale free network. The highly connected nodes highlighted a group of known onco-miRNAs (e.g. hsamiR- 183*) and tumor suppressor miRNAs (e.g. hsa-miR-34a), as well as some well-known cancer related GO biological processes (e.g. apoptosis). Interestingly, we found that chemotherapeutic drug treatment can counteract the disregulated CoMi activity in the cancer-specific network. For instance, 100% of down-regulated CoMi activities in a "core" breast cancer network contains apoptosis-related GO terms that could be counteracted by Paclitaxel treatment. To perform in silico drug screening, the similarity of a query CoMi activity signature (e.g. differential CoMi activity in cancer vs. normal) to each of the reference CoMi activities (converted from reference mRNAs expression profiles in the Connectivity Map) was assessed. We found that the most negatively correlated compounds significantly overlapped with known cancer drugs. Conclusions: By defining a Stability Index for in silico drug screening, we found CoMi activity signatures strikingly outperformed the traditional CMAP method or mRNA-based signatures. Thus, the dynamic remodeling of context-specific miRNAs regulation network could reveal the hidden miRNAs that act as key mediators of drug action and facilitate in silico cancer drug screening. © 2011 IEEE.

In silico drug repositioning based on drug-miRNA associations

Drug repositioning by applying 'expression profiles' generated by integrating chemical structure similarity and gene semantic similarity.

Drug repositioning based on the target microRNAs using bilateral-inductive matrix completion

Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm

In Silico Drug Repositioning Using Deep Learning and Comprehensive Similarity Measures

Computational Drug Repositioning Using Meta-Path-based Semantic Network Analysis.

Computational Drug Repositioning Using Collaborative Filtering Via Multi-Source Fusion

Predicting potential treatments for complex diseases based on miRNA and tissue specificity

A Pathway Profile-Based Method for Drug Repositioning

Drug Repositioning By Kernel-Based Integration Of Molecular Structure, Molecular Activity, And Phenotype Data

Computational drug repositioning based on the relationships between substructure–indication

Prediction of drug-target interactions for drug repositioning only based on genomic expression similarity

Computational Drug Repositioning Based on Multi-Similarities Bilinear Matrix Factorization.

A Computational Strategy for Drug Repositioning Based on Support-Vector Regression Algorithm

Predicting drug-disease associations by network embedding and biomedical data integration.

Biomedical Data and Computational Models for Drug Repositioning: a Comprehensive Review

Dynamic remodeling of context-specific miRNAs regulation networks facilitate in silico cancer drug screening

Computational drug repositioning using low-rank matrix approximation and randomized algorithms

DrugRepPT: a Deep Pre-Training and Fine-Tuning Framework for Drug Repositioning Based on Drug's Expression Perturbation and Treatment Effectiveness.

Computational Drug Repositioning with Random Walk on a Heterogeneous Network

deepDR: a network-based deep learning approach to in silico drug repositioning